ALK upgrades guidance following convincing sales and savings
Allergy company ALK is turning up its guidance for the company's revenue and earnings for the whole year after sales have surprised positively, and after the firm has saved money on expenses and on timing its clinical development activities differently.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Allergy and immune therapy company ALK reports better sales than predicted for the second quarter of the year. The company has also saved some money on certain expenses and on postponing certain clinical activities, so now the Danish company is upgrading its revenue and earnings guidance for full-year 2021, according to a Monday press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK nominates former Sanofi executive for board membership
For subscribers
